2023 World Conference on Lung Cancer (Posters)-EP13.03. RWD of Atezolizumab Plus Chemotherapy in First Line SCLC

Pdf Summary

A multicenter retrospective study was conducted to assess the real-world use of atezolizumab plus chemotherapy in small-cell lung cancer (SCLC) patients. The study included 118 patients diagnosed with SCLC between October 2021 and November 2022. All patients received first-line treatment with a combination of atezolizumab and chemotherapy. The majority of patients were males with a median age of 64 years. Most patients had an ECOG performance status of 0-1 at the beginning of treatment, and all patients had a history of smoking. Approximately 50% of patients had a previous diagnosis of chronic obstructive pulmonary disease (COPD).<br /><br />The study observed that the most frequent location of the primary tumor was the right side, and all patients had metastatic disease, with the most common sites of metastasis being the bone, liver, lung, adrenal gland, and brain. With a median follow-up of 16 months, the median overall survival was 9.5 months, and the progression-free survival for the first-line treatment was 5 months. The most frequently used therapeutic regimen was carboplatin in combination with etoposide and atezolizumab.<br /><br />The study also found that 60% of patients received radiotherapy at some point during their treatment, with holocranial radiotherapy being the most common. Only 27.4% of patients received prophylactic cranial irradiation. The average number of chemotherapy cycles was 4, while the average number of atezolizumab cycles was 5. The majority of patients showed a partial response to treatment, and only a small percentage experienced disease progression. Approximately 40.7% of patients received second-line treatment, with platinum retreatment and irinotecan being the most commonly prescribed regimens.<br /><br />In conclusion, this real-world study confirms the benefits of adding atezolizumab to chemotherapy as a first-line treatment for SCLC patients. The study provides valuable insights into the use of this treatment regimen in a population with important comorbidities and real-world therapeutic management.

Asset Subtitle

Ruth Alvarez Cabellos

Meta Tag

Speaker Ruth Alvarez Cabellos

Topic SCLC & Neuroendocrine Tumors: First Line Therapy

Keywords

multicenter study

atezolizumab

chemotherapy

small-cell lung cancer

SCLC

real-world use

patient characteristics

metastatic disease

overall survival

progression-free survival